<DOC>
	<DOCNO>NCT00661427</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , 2 dos Cetuximab head neck cancer . The study do 250 mg/m2 give weekly work well . Doses high 700 mg/m2 every week appear toxic , try determine 500 mg/m2 750 mg/m2 give every week work well . We know help . We use learn research study help people disease .</brief_summary>
	<brief_title>Cetuximab Either 500 750 mg/m2 Every Other Week Recurrent Metastatic Head Neck Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>sign informed consent HIPAA authorization histologically confirm squamous cell cancer head neck At least 21 day must elapse administration prior chemotherapy recurrent/metastatic disease . measurable disease define RECIST ECOG PS ≤ 2 Adequate hematologic function define ANC &gt; = 1200/mm3 , platelet count ≥ 100,000 obtain within 14 day prior enrollment . Adequate hepatic function define t. bilirubin ≤ 1.5 mg/dl , transaminases &amp; alk phos ≤ 5x ULN obtain within 14 day prior enrollment . Adequate renal function define serum creatinine ≤ 1.5 x ULN creatinine clearance &gt; 40 mL/minute . Women childbearing potential must agree use accepted effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration study negative pregnancy test within 7 day prior registration . If male sexually active , patient agrees use effective contraception . Accessible treatment followup . Patients enrol trial must treat participate center . Patients treat CNS metastasis may eligible fully recover radiation therapy , surgery steroid prescribe CNS metastasis . Known , uncontrolled CNS metastasis . CT/MRI brain require unless CNS metastasis suspect clinically . prior cetuximab therapy set recurrence refractory disease Other active invasive malignancy , nonmelanoma skin cancer situ cervical cancer . Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy . Ongoing active clinically serious infection &gt; CTCAE Grade 2 require IV antibiotic , symptomatic congestive heart failure , unstable angina pectoris , unstable cardiac arrhythmia , ( patient stable ratecontrolled atrial fibrillation may eligible ) medical condition , opinion investigator , would compromise safety patient compromise patient 's ability complete study , psychiatric illness/social situation would limit compliance study requirement . elective plan major surgery perform course trial pregnant lactate woman employee investigator study center w/ direct involvement study study direction study center , well family member employee More two prior cytotoxic regimens metastatic/recurrent disease . Known hypersensitivity reaction mouse antibody . Patients nasopharyngeal cancer exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Head Neck cancer</keyword>
	<keyword>Cetuximab</keyword>
</DOC>